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Abstract
A fundamental challenge in human health is the identification of disease-causing genes. Recently, several studies have
tackled this challenge via a network-based approach, motivated by the observation that genes causing the same or similar
diseases tend to lie close to one another in a network of protein-protein or functional interactions. However, most of these
approaches use only local network information in the inference process and are restricted to inferring single gene
associations. Here, we provide a global, network-based method for prioritizing disease genes and inferring protein complex
associations, which we call PRINCE. The method is based on formulating constraints on the prioritization function that relate
to its smoothness over the network and usage of prior information. We exploit this function to predict not only genes but
also protein complex associations with a disease of interest. We test our method on gene-disease association data,
evaluating both the prioritization achieved and the protein complexes inferred. We show that our method outperforms
extant approaches in both tasks. Using data on 1,369 diseases from the OMIM knowledgebase, our method is able (in a
cross validation setting) to rank the true causal gene first for 34% of the diseases, and infer 139 disease-related complexes
that are highly coherent in terms of the function, expression and conservation of their member proteins. Importantly, we
apply our method to study three multi-factorial diseases for which some causal genes have been found already: prostate
cancer, alzheimer and type 2 diabetes mellitus. PRINCE’s predictions for these diseases highly match the known literature,
suggesting several novel causal genes and protein complexes for further investigation.
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Introduction
Associating genes with diseases is a fundamental challenge in
human health with applications to understanding disease mech-
anisms, diagnosis and therapy. Linkage studies are often used to
infer genomic intervals that are associated with a disease of
interest. Prioritizing genes within these intervals is a formidable
challenge and computational approaches are becoming the
method of choice for such problems.
When one or more genes were already implicated in a given
disease, the prioritization task is often handled by computing the
functional similarity between a given gene and the known disease
genes. Such a similarity can be based on sequence [1], functional
annotation [2], protein-protein interactions [3,4] and more (see [5]
for a comprehensive review of these methods). When no causal
genes are known, the prioritization is done by exploiting the
modular view described above, comparing a candidate gene to
other genes that were implicated in similar diseases.
Approaches in the latter category are often based on a measure of
phenotypic similarity (see, e.g., [6,7]) between the disease of interest
and other diseases for which causal genes are known. This is
motivated by the observation that genes causing the same or similar
diseases often lie close to one another in a protein-protein
interaction network [3,5]. Lage et al. [7] score a candidate protein
with respect to a disease of interest based on the involvement of its
direct network neighbors in a similar disease. The protein and its
high-confidence interactors are also suggested to form a putative
protein complex that is related to the disease.Kohleret al. [8]group
diseases into families. For a given disease, they employ a random
walk from known genes in its family to prioritize candidate genes.
Finally, Wu et al. [9] score a candidate gene g for a certain disease d
based on the correlation between the vector of similarities of d to
diseases with known causal genes, and the vector of closeness in a
protein interaction network of g and those known disease genes. A
recent follow-up work by Wu et al. introduces AlignPI, a method
that exploits known gene-disease associations to align the pheno-
typic similarity network with the human PPI network [10]. The
alignment is used to identify local dense regions of the PPI network
and their associated disease clusters. The authors show the utility of
their framework in causal gene prediction.
Most of these methods focus on prioritizing independent genes;
however, in many cases, mutations at different loci could lead to
the same disease. This genetic heterogeneity may reflect an
underlying molecular mechanism in which the disease-causing
genes form some kind of a functional module (e.g., a multi-protein
complex or a signaling pathway) [7,11]. For example, Fanconi
anemia is a heterogeneous syndrome for which seven of its causing
genes are known to form a protein complex which functions in
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to the inference of larger disease-related machineries, revealing
important mechanistic insights on the disease of interest.
While the above methods that integrate protein-protein
interaction (PPI) information with a phenotypic similarity measure
have been shown to outperform previous prioritization approach-
es, they are limited in their application. Specifically, both AlignPI
and the method of Lage et al. consider only small localized regions
of the PPI network and do not capture global network signals. The
methods of Kohler et al. and Wu et al. tackle the prioritization task
only, and do not suggest ways to reveal the protein modules that
are affected in a given disease.
In this work we tackle both challenges. We present a novel
network-based approach for predicting causal genes and protein
complexes that are involved in a disease of interest. The method,
which is called PRINCE (PRIoritizatioN and Complex Elucida-
tion), generalizes the network-based approaches above by both
considering the network signal in a global manner and going
beyond single genes to the modules that are affected in a given
disease. It receives as input a disease-disease similarity measure and
a network of protein-protein interactions. It uses a propagation-
basedalgorithm,apreliminaryversionofwhichappearedin[13],to
infer a strength-of-association scoring function that is smooth over
the network (i.e., adjacent nodes are assigned similar values) and
exploits the prior information on causal genes for the same disease
or similar ones. This process is illustrated in Figure 1. This scoring is
then used in combination with a PPI network to infer protein
complexes that are involved in the given disease.
We apply our method to analyze disease-gene association data
from the Online Mendelian Inheritance in Man (OMIM) [14]
knowledgebase. We test, in a cross-validation setting, the utility of
our approach in prioritizing genes for all diseases with at least one
known gene. We compare the performance of our method to two
state-of-the-art, recently published methods [8,9]. In all of our tests
PRINCE outperforms the other methods by a significant margin.
We then use our method to associate protein complexes with
disease. The complexes that we recover are shown to be highly
coherent in terms of the function, expression and conservation of
their member proteins. According to these measures the collection
of protein complexes we infer significantly outperforms a previous
collection suggested by Lage et al. [7], in which each complex was
limited to a protein and its direct interactors. Our complete set of
predictions of gene- and protein-complex associations is available
in the Supplementary Material (Suppl. Datasets S1, S2, S3).
We demonstrate the power of PRINCE by studying in detail
three multi-factorial diseases for which some causal genes have
been mapped already: Prostate Cancer, Alzheimer Disease and
Non-insulin-dependant Diabetes Mellitus (Type 2). For each
disease we investigate PRINCE’s top-10 predictions when
considering the entire network, and when limiting the search to
genomic intervals that have been associated with the disease. 69%
of these predictions are validated in the literature (using
independent data), leaving 18 suggestions for novel causal genes.
Results/Discussion
We designed a novel gene prioritization function, which
integrates protein-protein interaction (PPI) information with a
Figure 1. Illustration of the PRINCE algorithm. Aq u e r yd i s e a s e ,
denoted Q, has varying degrees of phenotypic similarity with other
diseases, denoted d1–d5 (marked with maroon lines, where thicker lines
represent higher similarity). Known causal genes for these similar diseases
are connected by dashed blue lines and used as the prior information.
p1–p11 comprise the protein set of a protein-protein interaction network,
where interactions are marked with black lines and thicker lines denote
edges with higher confidence. A scoring function that is smooth over the
network is computed using an iterative network propagation method. At
every iteration of the algorithm, each protein pumps flow to its neighbors
and receives flow from them. Protein colors correspond to the flow they
receive in a specific iteration, the darker the color the higher the flow. (A):
the flow after the first iteration, representing the prior information. Only
proteins p2, p4 & p9, which are directly associated with similar diseases,
have a positive incoming flow. (B): After several iterations, the amount of
flow to each node converges, and the resulting flow, used to score the
proteins, appears to be smooth over the network. p5 emerges as the best
causal gene candidate for disease Q, as it interacts with both p2 and p4.
doi:10.1371/journal.pcbi.1000641.g001
Author Summary
Understanding the genetic background of diseases is
crucial to medical research, with implications in diagnosis,
treatment and drug development. As molecular approach-
es to this challenge are time consuming and costly,
computational approaches offer an efficient alternative.
Such approaches aim at prioritizing genes in a genomic
interval of interest according to their predicted strength-
of-association with a given disease. State-of-the-art prior-
itization problems are based on the observation that
genes causing similar diseases tend to lie close to one
another in a network of protein-protein interactions. Here
we develop a novel prioritization approach that uses the
network data in a global manner and can tie not only
single genes but also whole protein machineries with a
given disease. Our method, PRINCE, is shown to outper-
form previous methods in both the gene prioritization task
and the protein complex task. Applying PRINCE to prostate
cancer, alzheimer’s disease and type 2 diabetes, we are
able to infer new causal genes and related protein
complexes with high confidence.
PRINCE: Associating Genes & Complexes with Disease
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proteins with a disease of interest. The scoring is designed to be
smooth over the PPI network, meaning that adjacent nodes are
assigned with similar values, and to exploit prior information on
the involvement of proteins in the same or similar diseases. As
further detailed in the Methods section, the scoring is done by
simulating an iterative process where proteins for which prior
information exist, pump flow to their network neighbors. In
addition, every protein propagates the flow received in the
previous iteration to its neighbors. The final score of each protein
is determined by the amount of flow it has, which is guaranteed to
converge.
Comparison to other methods
In order to perform a comprehensive comparison of our
approach to extant ones on the same input data, we reimple-
mented two state-of-the-art global approaches for gene prioritiza-
tion introduced earlier: the random-walk based method of [8] and
the Cipher algorithm [9]. We could not reimplement the method
of Lage et al. [7], as it has many parameters that had to be
returned to fit our data, and a code for this method was not readily
available.
To evaluate the performance of the different methods, we used
a leave-one-out cross validation procedure. In each cross-
validation trial, we removed a single disease-protein association
from the data, and each algorithm was evaluated by its success in
reconstructing the hidden association, i.e., by the rank it assigned
to a protein when querying the disease it is associated with (for
further details on the cross-validation process see Methods). To
simulate the case of prioritizing proteins encoded by genes inside a
linkage interval, we followed [8] and artificially constructed for
each protein associated with a disease an interval of size 100
around it. We evaluated the performance of an algorithm in terms
of overall precision versus recall when varying the rank threshold
1ƒkƒ100. Precision is the fraction of true gene-disease associa-
tions that ranked within the top k% in the corresponding trial of
the cross validation procedure. Recall is the fraction of trials in
which the hidden association was recovered as one of the top k%
scoring ones.
We tested our method on all 1,369 diseases with a known causal
gene in the OMIM database. The results of applying the different
methods are depicted in Figure 2. Our algorithm achieved the best
performance, ranking the correct gene as the top-scoring one in
34% of the cases. Random-walk and Cipher methods achieved
inferior results with 28.8% and 24.7% success rates, respectively.
This trend was maintained when performing 2-fold, 5-fold and
10-fold cross validation (Suppl. Figure S1).
Interestingly, even though our score does not directly indicate
the probability of a successful prediction, we noticed a significant
difference in the score distribution of top-1 correct predictions and
top-1 incorrect prediction in the cross validation setting (see Suppl.
Figure S2). Namely, about 75% of our correct top-1 predictions
received a score higher than 0:021, whereas about 75% of our
incorrect top-1 predictions received a score lower than that value.
In the top-1 case, if all of the predictions with a score lower than
0:021 are discarded, PRINCE’s precision is boosted to 61:8%,
whereas the recall decreases to 26:3%.
To further validate the predicted associations, we collected
recently published gene-disease associations that were not part of
our original data set. We obtained 51 new associations for 47
diseases with previously known causal genes, and 10 new
associations for diseases where the causal gene was unknown at
the time of the original data collection. On the first association set,
PRINCE ranked one of the newly associated genes as the top
scoring one in 20 of the 47 diseases (43%). On this set, PRINCE
significantly outperforms CIPHER and compares favorably to
Random Walk (Suppl. Figure S3), providing higher precision and
recall for k§2. On the second association set, PRINCE ranked
the newly associated gene as the top scoring one in two of the ten
diseases, and ranked the true causal gene higher than or equal to
the other methods in four additional cases, thus providing the best
average ranking (Suppl. Table S1).
Inferring novel causal genes for Prostate Cancer,
Alzheimer and Diabetes
Having validated our method, we proceeded to execute our
algorithm on specific multifactorial diseases that are linked to
multiple genomic regions. We selected Prostate Cancer (MIM:
176807), Alzheimer’s disease (MIM: 104300) and Diabetes
Mellitus, type 2 (MIM: 125853) as our three case studies. We
ranked candidate genes both over the entire PPI network, and
over genomic intervals to which the phenotype has been mapped
but no causal gene was identified, and analyzed our top-10
predictions in each case (Suppl. Table S2).
We checked whether our predicted genes were already found to
be involved with their query disease by searching online databases
[14–16] and scientific publications. In all of the three test cases, the
vast majority of top candidate genes over the entire network were
already known to be involved with the disease. These often
included the ‘usual suspects’ for the relevant disease family. For
example, the top predictions for Prostate Cancer included BRCA1,
TP53 and NBN, which are tumor suppressors involved in several
types of cancer. Over half of the top candidates from the
associated intervals were already implicated in the corresponding
diseases. Our ranking provides further support for their involve-
ment in the investigated diseases. In addition, PRINCE yields
several top scoring candidates that were not previously associated
with these diseases, providing viable candidates for further
research.
Going beyond the above three test cases, we applied our
algorithm to all 916 disorders in OMIM with an associated
interval and for which no causal gene is known. The complete set
of results is provided in the Supplementary Material (Suppl.
Dataset S1).
Figure 2. A comparison of prioritization algorithms. Perfor-
mance comparison for PRINCE, Random Walk and CIPHER in a leave-
one-out cross-validation test over 1,369 diseases with a known causal
gene. The figure shows recall versus precision when considering the top
k% proteins for various values of k.
doi:10.1371/journal.pcbi.1000641.g002
PRINCE: Associating Genes & Complexes with Disease
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Often, as alluded to above, mutations in multiple proteins that
form a protein complex or a pathway may lead to the same
disease. Thus, we sought to exploit the prioritization function we
have developed for the complex inference task. To this end,
starting with the set of proteins whose prioritization score is above
a threshold, we look for densely connected subsets that may form a
protein complex. The search is aided by a likelihood-based scoring
of protein complexes that takes into account the reliability of the
PPI interactions and the degrees of the network proteins
(Methods). As we show in Suppl. Figures S4 and S5, this score
correlates well with the coherency of the identified complexes (see
below). Applying this scheme to the OMIM diseases we predicted
566 complexes for diseases in which a causal gene is known and
137 complexes for diseases for which only an associated genomic
interval is known.
To test the biological plausibility of the identified complexes we
evaluated their coherency with respect to several attributes of their
member proteins (Methods). These measures quantify the extent to
which proteins in a complex share the same functional annotation,
have similar expression patterns under multiple conditions, and
have similar phylogenetic profiles, respectively. As a baseline, we
compared these measures with those computed for: (i) a set of
manually annotated protein complexes obtained from the Gene
Ontology (GO) annotation [17]; (ii) a set of protein clusters that are
not necessarily disease-related, obtained by applying the MCL
algorithm[18] tothe PPInetwork;and(iii)asetofpredicteddisease-
related complexes (Lage et al. [7])(Methods).
To allow a fair comparison between our results and those of
Lage et al., we focused on a subset of the identified complexes of
the same size as that provided by Lage et al. (80 for the case of a
known causal gene, and 59 for the case of a known locus;
Methods). The subset was constructed by computing the likelihood
score of each complex and choosing the highest ranking
complexes.
We found that the complexes predicted using our propagation
approach exhibited higher coherencies than the collection of Lage
et al. with respect to most measures (with the exception of
conservation coherency in the known-locus case). Notably, both
our collection and that of Lage et al. outperformed the PPI-based
collection produced by MCL, demonstrating the importance of
the disease association data in the protein complex inference
process. Moreover, our results were comparable to, and in some
cases better than, the manually curated collection, again testifying
to its high quality. These results are summarized in Table 1.
As a further validation of the complexes inferred by PRINCE,
we searched OMIM for evidence for the possible involvement of
the proteins of a complex in the diseases associated with it.
Specifically, for each complex, we scanned the OMIM entries of
the diseases associated with at least one complex member. For
each such disease, we checked whether any complex member that
is not known to be associated with that disease, is mentioned in its
entry. We found such support for 61% of the predicted complexes,
with an average of 3.6 genes per complex whose involvement was
corroborated in this manner. For comparison purpose, we
permuted the gene names and repeated the analysis on the
resulting random complexes. Only 7% of these random sets were
supported by OMIM, with an average of 1.6 evidences per set.
Three example putative protein complexes and their associated
diseases are shown in Figure 3. The first putative protein complex
(Figure 3(a)) was generated for the query disease Ataxia-
Telangiectasia (MIM:208900), which is associated with the gene
ATM. The putative complex contains 11 proteins which are all
known to be involved in response to DNA damage stimulus.
Except for CHEK2, all of them are directly involved in DNA
repair. All 7 diseases associated to those genes (among them are
Breast Cancer, Li-Fraumeni syndrome and Fanconi Anemia) are
known to be tightly coupled with mutations in DNA-repair related
genes. In this specific case it may be that these proteins do not
form a single complex in-vivo, but rather span a dense region of
the PPI network due to their central role as master regulators
(especially ATM and TP53) of reactions to DNA damage.
The second complex (Figure 3(b)) was generated for the query
disease Hereditary Prostate Cancer type 8 (HPC8, MIM:602759),
for which the causal gene is presently unknown. The complex’s
proteins are associated with several Colorectal Cancer variants
and Endometrial cancer. The genes associated with the Colorectal
and Endometrial cancers are from the MLH (MutL analog) and
PMS families which are involved in DNA mismatch repair. MLH1
and PMS2 form a Heterodimer, which interacts via MLH1 with
EXO1 (Exonuclease1), which also participates in DNA mismatch
repair. The gene coding for EXO1 is located at genetic locus 1q43,
which lies within the region associated with HPC8 (1q42.2–q43).
Moreover, EXO1 was ranked first by PRINCE in this interval. In
this case, the inferred protein complex provides support also to the
prediction that EXO1 is a causal gene for prostate cancer (MIM:
176807) discussed in the previous subsection.
The last complex (Figure 3(c)) was generated for the query
disease Microcephalic Osteodysplatic Primordial Dwarfism
(MOPD-I, MIM:210710), which has no known causal genes.
Two of the predicted complex’s genes are associated with two
hereditary diseases characterized by developmental delay and
physical deformations: ERCC5 with Cockayne Syndrome type A,
and ERCC2 with Cerebrooculofacioskeletal Syndrome 1. The
genes in the complex are all involved in DNA damage repair:
ERCC2, ERCC3, GTF2H1 and GTF2H2 are subunits of the core-
TFIIH basal Transcription Factor, and ERCC5 forms a stable
complex with TFIIH enabling recruitment of the Transcription
Factor for repairing UV damage [19]. ERCC3, one of the
predicted complex’s members, lies within the genetic locus
associated with MOPD-I, and is ranked as the best causal gene
candidate for MOPD-I among the genes at that locus by
PRINCE.
Conclusions
PRINCE is a powerful method for prioritizing genes and
protein complexes for a disease of interest. We have demonstrated
its power both in a cross validation setting and by closely
examining its predictions over complex, polygenic hereditary
Table 1. Coherency comparison of different protein complex
collections.
Functional
coherency (%)
Expression
coherency (%)
Conservation
coherency (%)
Known complexes 88.7 47.4 1.6
PPI-based complexes 48.1 12.4 0.2
Lage et al., gene known 77.5 18.9 3.75
Lage et al., locus known 74.6 18.2 6.8
PRINCE, gene known 95 43.8 17.5
PRINCE, locus known 89 35.6 1.7
Percentages represent the fraction of complexes whose coherency score passes
a certain significance threshold (pv0:05 after correcting for multiple hypothesis
testing). The best result in each column appears in bold.
doi:10.1371/journal.pcbi.1000641.t001
PRINCE: Associating Genes & Complexes with Disease
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proteins and their connecting edges represent protein-protein interactions. Diseases are denoted by square nodes, connected by phenotypic
similarity edges. Green dashed edges represent known gene-disease associations; red edges connect a disease to a gene that lies within its associated
genomic interval. The complexes were generated for the query diseases (A) Ataxia-Telangiectasia, (B) Hereditary Prostate Cancer type 8 and (C)
MOPD-I.
doi:10.1371/journal.pcbi.1000641.g003
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approach, combined with a novel normalization of protein-protein
interaction weights and disease-disease similarities.
While the results of PRINCE are promising, several of its
limitations should be acknowledged. First, PRINCE relies on prior
phenotypic information, which limits its application to diseases
that are phenotypically similar to diseases with known causal
genes. Second, PRINCE uses known gene-disease associations in
its computation, but other relevant data, such as genes that are
differentially expressed in the disease state, are not taken into
account. Combining such data into the prioritization process, e.g.,
using the method of [20], could increase the prediction power.
Last, PRINCE depends on accurate and comprehensive protein-
protein interaction data. As such data accumulate, the applicabil-
ity and accuracy of PRINCE are expected to grow.
Methods
Computing the prioritization function
The input to a gene prioritization problem consists of a set A of
gene-disease associations; a query disease q; and a protein-protein
interaction network G~(V,E,w), where V is the set of proteins, E
is the set of interactions and w is a weight function denoting the
reliability of each interaction. The goal is to prioritize all the
proteins in V (that are not known to be associated with q) with
respect to q.
For a node v[V, denote its direct neighborhood in G by N(v).
Let F : V?< represent a prioritization function, i.e., F(v) reflects
the relevance of v to q. Let Y : V?½0,1  represent a prior
knowledge function, which assigns positive values to proteins that
are known to be related to q, and zero otherwise.
Intuitively, we wish to compute a function F that is both smooth
over the network, i.e., adjacent nodes are assigned with similar
values, and also respects the prior knowledge, i.e., nodes for which
prior information exists should have similar values of F and Y.
Formally, we express the requirements on F as a combination of
these two conditions:
Fv ðÞ ~a
X
u[N(v)
Fu ðÞ w’ v,u ðÞ
"#
z 1{a ðÞ Yv ðÞ ð 1Þ
where w’ is a normalized form of w (described below). The
parameter a[(0,1) weighs the relative importance of these
constraints with respect to one another.
The requirements on F can be expressed in linear form as
follows:
F~aW’Fz(1{a)YuF~(I{aW’)
{1(1{a)Y ð2Þ
where W’ is a jVj|jVj matrix whose values are given by w’, and
F and Y are viewed here as vectors of size jVj. We require the
eigenvalues of W’ to be in ½{1,1 . Since a[(0,1), the eigenvalues
of (I{aW’) are positive and, hence, (I{aW’)
{1 exists.
While the above linear system can be solved exactly, for large
networks an iterative propagation-based algorithm works faster and
is guaranteed to converge to the system’s solution. Specifically, we
use the algorithm of Zhou et al. [21] which at iteration t computes
Ft : ~aW’Ft{1z(1{a)Y
where F1 : ~Y. This iterative algorithm can be best understood as
simulating a process where nodes for which prior information exists
pump information to their neighbors. In addition, every node
propagates the information received in the previous iteration to its
neighbors.
We chose to normalize the weight of an edge by the degrees of
its end-points, since the latter relate to the probability of observing
an edge between the same end-points in a random network with
the same node degrees. Formally, define a diagonal matrix D such
that D(i,i) is the sum of row i of W. We set W’~D{1=2WD{1=2
which yields a symmetric matrix where W’ij~Wij=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
D(i,i)D(j,j)
p
.
Note that W’ is similar to the stochastic matrix D{1W. Since
similar matrices have the same eigenvalues, and since a stochastic
matrix’s eigenvalues are in ½{1,1  (according to the Perron-
Frobenius theorem), the eigenvalues of W’ are indeed in ½{1,1 .
Incorporating disease similarity information
To determine the prior information vector Y, we used the
similarity metric computed by van Driel et al. [6]. This metric
spans 5,080 diseases in the OMIM [14] knowledgebase and is
based on their medical subject headings description.
van Driel et al. tested the predictive power of different ranges of
similarity values by calculating the correlation between the
similarity of two diseases and the functional relatedness of their
causal genes. According to their analysis, similarity values in the
range ½0,0:3  are not informative, while for similarities in the range
½0:6,1  the associated genes show significant functional similarity.
These empirical findings motivated us to represent our
confidence that two diseases are related using a logistic function
L(x)~
1
1ze(cxzd), such that for x[½0,0:3 , L(x)&0, and for
x[½0:6,1 , L(x)&1. This implies that L(0) needs to be close to 0.
We set L(0)~0:0001, which determines d as log(9999), and
tuned the parameter c using cross validation (see Parameter
Tuning Section below).
We used L to compute the prior knowledge Y in the following
way: for a query disease q and a protein v associated with a disease
p, we set Y(v)~L(S(q,p)), where S(q,p) is the similarity between
q and p.I fv is associated with several diseases, we choose the
disease p which is the most similar to q.
Experimental setup
We extracted 1599 known disease-protein associations from
GeneCards [15] spanning 1369 diseases and 1043 proteins. We
considered only disease-protein relations that included proteins
from the network and such that the relations are known to be
causative to avoid associations made by circumstantial evidence.
We constructed a human PPI network with 9998 proteins and
41072 interactions that were assembled from three large scale
experiments [22–24] and the Human Protein Reference Database
(HPRD) [25]. The interactions were assigned confidence scores
based on the experimental evidence available for each interaction
using a logistic regression model adapted from [26]. We used the
obtained scores to construct the adjacency matrix W.
To simulate the case of prioritizing proteins encoded by genes
inside a linkage interval, we followed [8] and artificially constructed
for each protein associated with a disease an interval of size 100
around it. We used the protein scores obtained from the output of
the algorithm to prioritize proteins residing in that interval.
To evaluate the performance of the different methods in
predicting gene-disease association, we used a leave-one-out cross
validation procedure. In each cross-validation trial, we removed a
single disease-protein association Sd, pT from the data, and in
addition all other disease-protein associations involving protein p.
An algorithm was evaluated by its success in reconstructing the
hidden association, i.e. by the rank it assigned to protein p when
PRINCE: Associating Genes & Complexes with Disease
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avoid ‘‘easy’’ cases in which p is also associated with other diseases
that are very similar to d.
Parameter tuning for gene prioritization
Our algorithm has three parameters that should be tuned: (i) c –
the parameter controlling the logistic regression transformation; (ii)
a – controlling the relative importance of prior information in the
association assignment; and (iii) the number of propagation
iterations employed. We tested the effect of these parameters on
the performance of the algorithm in a cross validation setting. The
precision-recall plots for the general disease case are depicted in
Suppl. Figure S6. By this figure, the optimal regression coefficient
is c~{15, implying that similarity values below 0.3 are assigned
with very low probability (v0:002), in accordance with the
analysis of [6]. The algorithm is not sensitive to the actual choice
of a as long as it is above 0.5 (panel b). Finally, the algorithm shows
fast convergence, achieving optimal results after ten iterations only
(panel c).
Implementation of random-walk and Cipher
The random-walk based approach requires disease grouping
information. To allow it to run on the more comprehensive disease
similarity data we had, we generalized the approach to use these
similarities (transformed by the logistic function L) as initial
probabilities for the random walk. The parameter r of the method,
which controls the probability for a restart, as well as our
transformation parameter c, were optimized using cross-validation
(as in the Parameter Tuning Section above). Note that Kohler et
al. suggested a second, diffusion-kernel based approach, which was
shown to be inferior to the random walk one, hence we did not
include it in our comparison. Also note that our propagation-based
method reduces to a random walk under appropriate transforma-
tions of the edge weights and prior information.
The Cipher method [9] is based on computing protein
closeness in a PPI network. Two variants of the algorithm were
suggested: Cipher-DN, which considers only direct neighbors in
the closeness computation, and Cipher-SP, which is based on a
shortest path computation. The former was shown to outperform
the latter, and hence we implemented this variant (Cipher-DN)
only.
Identifying protein complexes
Given a disease and a prioritization score for all the network
proteins, we aim at inferring densely connected protein complexes
that contain high scoring proteins. To this end, we start with the
top 100 scoring proteins within the entire network as complex
seeds (The method is not sensitive to the number of initial top
scoring proteins, and produces similar results for numbers in the
range 50–150; data not shown). We filter all seeds whose score is
below a prespecified threshold t or that were already associated
with the disease in a previously detected complex. To each seed we
iteratively add a neighboring protein with the highest score, as
long as this score is greater than t, and up to 20 proteins per seed
(about twice the average size of known protein complexes; a
similar bound was used in previous works [26,27]). At this stage, in
the case that the query disease has no known gene, but has an
interval associated to it, the computed complex is discarded if it
contains no member from that interval.
After an initial list of putative complexes is formed, a
refinement phase takes place where proteins are removed from
a putative complex to ensure that not only is the suggested
complex disease-related but also its member proteins are densely
interacting and, thus, constitute a good candidate for a complex.
To this end, we use the following likelihood-based scoring scheme
taken from [28]:
L(C)~
X
(u,v)[E(C)
log
b
p(u,v)
z
X
(u,v)= [E(C)
log
1{b
1{p(u,v)
where C is a putative complex and E(C) are its edges. Briefly, the
score is the log likelihood ratio between a protein complex model
(assuming that every two proteins in a complex should interact with
a high probability b, independently of all other pairs) and a random
set model (where connections in the sub-network arise at random,
with a probability proportional to the proteins’ degrees). This score
was further enhanced, as in [28] to accommodate for information
on the reliability of interactions. In brief, the interaction status of
every protein pair was treated as a noisy observation, and its
reliability was combined into the likelihood score. The b parameter
of the scoring scheme was set to 0.9, although results were not
sensitive to the actual parameter used as shown in Suppl. Table S3.
At each refinement step, we search for a protein whose removal
increases the score the most while maintaining the connectivity of
the candidate complex. The refinement is done until no score
increase is possible (while maintaining connectivity). We filter
candidate complexes with less than four proteins (to ensure
statistical significance) or with w50% overlap with higher-scoring
candidates.
For identifying complexes we use the same a and c values we
used for prioritization, which were tuned using cross-validation.
An additional parameter, t, is used as a threshold that defines the
minimal score (computed using propagation) needed for a protein
to be included in any identified complex. This parameter was
tuned separately for the case in which a causal gene for the query
disease is known and for the case that no causal gene is unknown.
The tuning aimed to obtain a collection of complexes whose
average size is similar to that of the manually curated GO
complexes (8.85 after filtering complexes with sizev4 or
sizew20). The resulting value of t is 0.1 (average size of 8.3) for
the case where a causal gene is known, and 0.015 (average size of
8.5) for the case where no causal gene is known.
Evaluation of protein complex predictions
We compared the protein complexes inferred by PRINCE to
three other collections:
(a) A gold standard set of 70 manually annotated protein
complexes retrieved from GO [17], by considering the gene
product associations of all terms that descended from the
‘Protein Complex’ term (GO:0043234).
(b) A collection of 160 clusters of proteins, obtained by applying
Markov Clustering [18] to the PPI network and sampling
160 of its clusters while maintaining the same size
distribution as the 80 protein complexes inferred by
PRINCE for the known causal gene case.
(c) The collection of complexes published by Lage et al [7]. We
filtered this collection by removing complexes of sizev4 or
sizew20. We further filtered overlapping complexes as
described above. The filtering resulted in 80 complexes for
the known causal gene case, and 59 for diseases for which no
causal gene is known.
Following [29], we evaluated the different collections using
three coherency measures:
Functional coherency. The percent of functionally coherent
complexes based on the GO process annotation. For a given
(i)
(ii)
(iii)
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in C that are annotated with t (or with a more specific term). Let
p(t) be the hypergeometric probability for observing n(t) or more
proteins annotated with term t in a protein subset of size jCj.
Having found a term t0 with minimal probability p(t0), the score
was set to the empirical p-value of the enrichment under term t0,
computed by comparing p(t0) with the analogous probabilities for
10,000 random protein sets of size jCj. These latter p-values were
corrected for multiple complex testing using the False Discovery
Rate (FDR) procedure [30].
Expression coherency. The percent of expression coherent
complexes. Each protein complexes was scored by the mean
pairwise Pearson correlation of gene expression profiles [31]
among all its members. The statistical significance of the
expression coherency score was computed by comparing it to
similar scores obtained for randomly drawn protein sets of the
same size. These p-values were further FDR-corrected for multiple
complex testing.
Conservation coherency. The percent of conservation
coherent complexes. Phylogenetic profiles (i.e., presence/absence
patterns) of human genes in a set of 18 eukaryotic genomes were
obtained from NCBI’s HomoloGene database [32]. The
conservation coherency of a cluster was defined as the mean
pairwise Jaccard similarity among the phylogenetic profiles of the
cluster’s members. These scores were compared to those obtained
for randomly drawn protein sets of the same size and FDR-
corrected for multiple complex testing.
In all three cases, a complex was considered to be significantly
coherent if its corrected p-value was below a threshold of 0.05.
Hardware, performance and availability
The computational experiments were executed on a single core
of an AMD Opteron(tm) 2382 processor 2.6 Ghz. The average
runtime for completing the cross validation iterations or inferring
protein complexes was 1–2 minutes. The code and data sets
described herein are available upon request.
Supporting Information
Figure S1 K-fold cross validation comparison of PRINCE,
Random Walk and CIPHER. (a) 2-fold (b) 5-fold (c) 10-fold.
Found at: doi:10.1371/journal.pcbi.1000641.s001 (0.14 MB JPG)
Figure S2 Log-score distribution for genes (a) correctly and (b)
in-correctly ranked 1st by PRINCE during Leave-One-Out cross
validation trials.
Found at: doi:10.1371/journal.pcbi.1000641.s002 (0.01 MB PNG)
Figure S3 Performance comparison on 47 diseases with a known
causal gene, for which another causal gene was recently
discovered.
Found at: doi:10.1371/journal.pcbi.1000641.s003 (0.02 MB PNG)
Figure S4 Biological plausability scores for complexes inferred
from diseases with a known causal gene.
Found at: doi:10.1371/journal.pcbi.1000641.s004 (0.06 MB JPG)
Figure S5 Biological plausability scores for complexes inferred
from diseases with an associated genomic region and an unknown
causal gene.
Found at: doi:10.1371/journal.pcbi.1000641.s005 (0.06 MB JPG)
Figure S6 PRINCE algorithm parameters fine-tuning summary:
(a) Performance comparison for various logistic regression
parameters; (b) Performance comparison with varying iterations
count; (c) Performance comparison for various values of alpha.
Found at: doi:10.1371/journal.pcbi.1000641.s006 (0.16 MB JPG)
Table S1 Comparison of the ranking given by PRINCE,
Random Walk and CIPHER to recently discovered causal genes
for ten diseases for which no causal gene was known at the
inception of this research.
Found at: doi:10.1371/journal.pcbi.1000641.s007 (0.02 MB PDF)
Table S2 PRINCE’s causal gene predictions for Prostate
Cancer, Alzheimer’s Disease and type 2 Diabetes.
Found at: doi:10.1371/journal.pcbi.1000641.s008 (0.04 MB XLS)
Table S3 Comparing the effect of different values of beta on the
inferred complexes, in terms of functional enrichment, expression
coherency and conservation coherency.
Found at: doi:10.1371/journal.pcbi.1000641.s009 (0.02 MB PDF)
Dataset S1 Known loci disorders. PRINCE’s causal gene
predictions for 916 OMIM disorders with an associated interval
and without a known causal gene.
Found at: doi:10.1371/journal.pcbi.1000641.s010 (0.94 MB
TXT)
Dataset S2 Known gene complexes. 80 Protein Complexes
inferred for disorders with a known causal gene.
Found at: doi:10.1371/journal.pcbi.1000641.s011 (3 KB TXT)
Dataset S3 Known loci complexes. 59 Protein Complexes
inferred for disorders with an unknown causal gene and an
associated genomic interval.
Found at: doi:10.1371/journal.pcbi.1000641.s012 (2 KB TXT)
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